BIO-RAD LABORATORIES, INC.
Qualité des données : 100%
BIO-B
NYSE
Manufacturing
Measuring & Analyzing Instruments
277,00 €
0,00 €
(0,00%)
Cap. Boursière: 7,48 B
Prix
277,00 €
Cap. Boursière
7,48 B
Fourchette du Jour
277,00 € — 277,00 €
Fourchette 52 Semaines
225,29 € — 321,12 €
Volume
3
Ouverture 277,00 €
Moyenne 50J / 200J
279,39 €
0,85% below
Moyenne 50J / 200J
280,40 €
1,21% below
Quick Summary
Points Clés
Revenue declined -3,04% annually over 5 years
ROE of 10,96% — decent returns on equity
Net margin of 29,42% shows strong profitability
Debt/Equity of 0,18 — conservative balance sheet
Generating 374,60 M in free cash flow
P/E of 9,84 — trading at a low valuation
Croissance
Revenue Growth (5Y)
-3,04%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)0,65%
Earnings (1Y)N/A
FCF Growth (3Y)31,01%
Qualité
Return on Equity
10,96%
Au-dessus de la moyenne du secteur (-53,41%)
ROIC0,38%
Net Margin29,42%
Op. Margin1,83%
Sécurité
Debt / Equity
0,18
En dessous de la moyenne du secteur (0,31)
Current Ratio5,44
Interest Coverage0,96
Valorisation
PE (TTM)
9,84
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio1,11
EV/EBITDA38,96
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1364 pairs)
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1364 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 9,8 | -1,5 |
| P/B | 1,1 | 1,6 |
| ROE % | 11,0 | -53,4 |
| Net Margin % | 29,4 | -41,5 |
| Rev Growth 5Y % | -3,0 | 1,8 |
| D/E | 0,2 | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 0,65% | Revenue Growth (3Y) | -1,66% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -3,04% | Earnings Growth (5Y) | -34,96% |
| Profitability | |||
| Revenue (TTM) | 2,58 B | Net Income (TTM) | 759,90 M |
| ROE | 10,96% | ROA | 7,63% |
| Gross Margin | 51,87% | Operating Margin | 1,83% |
| Net Margin | 29,42% | Free Cash Flow (TTM) | 374,60 M |
| ROIC | 0,38% | FCF Growth (3Y) | 31,01% |
| Safety | |||
| Debt / Equity | 0,18 | Current Ratio | 5,44 |
| Interest Coverage | 0,96 | Asset Turnover | 0,26 |
| Working Capital | 2,32 B | Tangible Book Value | 5,77 B |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 9,84 | Forward P/E | N/A |
| P/B Ratio | 1,11 | P/S Ratio | 2,89 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 38,96 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 5,01% | ||
| Market Cap | 7,48 B | Enterprise Value | 8,28 B |
| Per Share | |||
| EPS (Diluted TTM) | 27,85 | Revenue / Share | 95,71 |
| FCF / Share | 13,88 | OCF / Share | 19,72 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | -33,28% |
| EPS CAGR (10Y) | 45,55% | ||
| Efficiency | |||
| CapEx / Revenue | 6,10% | FCF Conversion | 49,30% |
| SBC-Adj. FCF | 316,90 M | Growth Momentum | 3,69 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2,58 B | 2,57 B | 2,67 B | 2,80 B | 2,92 B |
| Net Income | 759,90 M | -1,84 B | -637,32 M | -3,63 B | 4,25 B |
| EPS (Diluted) | 27,85 | -25,57 | -21,82 | -121,79 | 140,56 |
| Gross Profit | 1,34 B | 1,38 B | 1,43 B | 1,57 B | 1,64 B |
| Operating Income | 47,20 M | 269,00 M | 337,80 M | 482,62 M | 489,43 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 275,60 M | 295,90 M | 247,43 M | 256,89 M | 271,66 M |
| SG&A Expenses | 844,30 M | 814,00 M | 841,72 M | 827,83 M | 879,57 M |
| D&A | 165,40 M | 151,60 M | 145,90 M | 137,30 M | 133,80 M |
| Interest Expense | 49,00 M | 48,90 M | 49,44 M | 38,11 M | 1,55 M |
| Income Tax | 235,60 M | -498,30 M | -212,78 M | -1,08 B | 1,19 B |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 10,58 B | 9,36 B | 12,30 B | 13,50 B | 17,78 B |
| Total Liabilities | 3,12 B | 2,79 B | 3,56 B | 3,89 B | 4,11 B |
| Shareholders' Equity | 7,45 B | 6,57 B | 8,74 B | 9,62 B | 13,67 B |
| Total Debt | 1,20 B | 1,21 B | 1,21 B | — | — |
| Cash & Equivalents | 529,80 M | 488,10 M | 403,82 M | 434,22 M | 470,78 M |
| Current Assets | 2,91 B | 3,03 B | 3,05 B | 3,16 B | 1,99 B |
| Current Liabilities | 517,00 M | 467,80 M | 522,80 M | 568,71 M | 680,94 M |
{"event":"ticker_viewed","properties":{"ticker":"BIO-B","listing_kind":"stock","pathname":"/stocks/bio-b","exchange":"NYSE","country":"US"}}